Blog

New Approaches to Adherence and Prevention of Dropouts: the Digital Era of Patient Engagement in Cardiometabolic Trials

This article describes how behavioral science can be applied in cardiometabolic clinical research to augment drug interventions. This combined approach addresses the Health Inequity gap while also increasing patient engagement.

New Approaches to Adherence and Prevention of Dropouts: the Digital Era of Patient Engagement in Cardiometabolic Trials Read More...

Navigating Patient-Reported Outcome (PRO) Data in Cancer Clinical Trials: Insights from the FDA’s Latest Guidance

The recent FDA publication “Submitting Patient-Reported Outcome (PRO) Data in Cancer Clinical Trials” represents a significant leap forward in cancer research and drug development. This detailed guidance for integrating PROs into the drug approval process sets a new standard for the evaluation of cancer treatments.

Navigating Patient-Reported Outcome (PRO) Data in Cancer Clinical Trials: Insights from the FDA’s Latest Guidance Read More...

Human Interaction: Risk-Mitigation Recommendations When Using Technology in Clinical Trials

Technological advancements have broadened the reach of clinical studies to larger and more diverse populations. However, technology alone isn’t sufficient to guarantee successful trial outcomes. The human element, including how technology is utilized by sites, sponsors, and patients in accordance with regulatory guidelines, remains pivotal in ensuring compliance, minimizing risks, and upholding patient safety.

Human Interaction: Risk-Mitigation Recommendations When Using Technology in Clinical Trials Read More...

Scroll to Top

Contact Clinical ink

Request more information, submit questions, set up a demonstration, and more.